ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
about
Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors.
P2860
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
ESR1 and ESR2 polymorphisms in ...... uence for early breast cancer.
@ast
ESR1 and ESR2 polymorphisms in ...... uence for early breast cancer.
@en
type
label
ESR1 and ESR2 polymorphisms in ...... uence for early breast cancer.
@ast
ESR1 and ESR2 polymorphisms in ...... uence for early breast cancer.
@en
prefLabel
ESR1 and ESR2 polymorphisms in ...... uence for early breast cancer.
@ast
ESR1 and ESR2 polymorphisms in ...... uence for early breast cancer.
@en
P2093
P2860
P1476
ESR1 and ESR2 polymorphisms in ...... uence for early breast cancer.
@en
P2093
Alan S Coates
Aron Goldhirsch
BIG 1-98 Collaborative Group
Beat Thürlimann
Bradley Long
Brandon Young
Brian Leyland-Jones
James M Rae
Karen N Price
Kathryn P Gray
P2860
P2888
P304
P356
10.1007/S10549-015-3634-6
P407
P577
2015-11-21T00:00:00Z